DBV Technologies (DBVT)
(Delayed Data from NSDQ)
$0.73 USD
+0.03 (4.27%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $0.78 +0.05 (6.85%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
DBVT 0.73 +0.03(4.27%)
Will DBVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DBVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DBVT
Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
DBVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study
Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
Other News for DBVT
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
Kepler Capital Sticks to Their Buy Rating for DBV Technologies (0QAJ)
Goldman Sachs Keeps Their Sell Rating on DBV Technologies (0QAJ)